A new drug that impairs the function of cancer-driving proteins may prove to be a new treatment for patients with lung cancer.
The drug, ganetespib, may also be effective for treating patients who have become resistant to the only FDA-approved targeted therapy for this disease, crizotinib, according to data published in iCancer Discovery/i, a journal of the American Association for Cancer Research.
"Lung cancer, a leading cause of death, is no longer thought of as a single disease, ...
A new drug that impairs the function of cancer-driving proteins may prove to be a new treatment for patients with lung cancer.
The drug, ganetespib, may also be effective for treating patients who have become resistant to the only FDA-approved targeted therapy for this disease, crizotinib, according to data published in iCancer Discovery/i, a journal of the American Association for Cancer Research.
"Lung cancer, a leading cause of death, is no longer thought of as a single disease, ...